Tohme Samer, Goswami Julie, Han Katrina, Chidi Alexis P, Geller David A, Reddy Srinevas, Gleisner Ana, Tsung Allan
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Pittsburgh Medical Center, Liver Cancer Center, 3459 Fifth Ave., 7 South, Pittsburgh, PA, 15213, USA.
Hepatobiliary and Pancreatic Surgery, Virginia Piper Cancer Institute-Allina Health, 800 East 28th Street, Ste 602, Minneapolis, MN, 55415, USA.
J Gastrointest Surg. 2015 Dec;19(12):2199-206. doi: 10.1007/s11605-015-2962-5. Epub 2015 Oct 5.
Previous studies have shown benefit not only from postoperative chemotherapy but also from a short interval to initiation of treatment after resection of primary colorectal cancer. The aim of this study was to determine difference in timing to postoperative chemotherapy for minimally invasive resection (MIR) vs. open resection (OR) of colorectal cancer liver metastases (CRCLM).
This is a retrospective review of 1:1 matched patients undergoing MIR (n = 66) and OR (n = 66) for CRCLM at a single institution.
Patients undergoing MIR of CRCLM had significantly shorter length of hospital stay, fewer major complications, and shorter interval to postoperative chemotherapy (median 42 vs. 63 days, p < 0.001). Univariable analysis showed that surgical approach, postoperative complications, blood loss, number of lesions, and length of stay were associated with timing to chemotherapy. On multivariable analysis, surgical approach was still associated with timing to chemotherapy, and postoperative complications resulted in a delay of chemotherapy among patients who underwent OR but not among those who underwent MIR. In addition, worse disease-free survival was seen among patients who received postoperative chemotherapy more than 60 days after surgery.
By modifying the deleterious effects of postoperative complications on timing of postoperative chemotherapy, patients undergoing MIR for CRCLM are treated with chemotherapy sooner after surgery compared to those undergoing OR.
既往研究表明,术后化疗不仅有益,而且在原发性结直肠癌切除术后较短时间内开始治疗也有好处。本研究的目的是确定结直肠癌肝转移(CRCLM)的微创切除(MIR)与开放切除(OR)术后化疗时机的差异。
这是一项对单一机构中因CRCLM接受MIR(n = 66)和OR(n = 66)的1:1匹配患者的回顾性研究。
接受CRCLM的MIR患者住院时间显著缩短,主要并发症更少,术后化疗间隔更短(中位数42天对63天,p < 0.001)。单变量分析显示,手术方式、术后并发症、失血量、病灶数量和住院时间与化疗时机相关。多变量分析显示,手术方式仍与化疗时机相关,术后并发症导致接受OR的患者化疗延迟,但接受MIR的患者未出现这种情况。此外,术后60天以上接受化疗的患者无病生存期较差。
通过改变术后并发症对术后化疗时机的有害影响,与接受OR的患者相比,接受CRCLM的MIR患者术后能更快接受化疗。